| Kinderhook Dental Arts Pc | |
|
2870 Us Highway 9 Valatie NY 12184-9401 | |
| (518) 758-7179 | |
| Not Available |
| Full Name | Kinderhook Dental Arts Pc |
|---|---|
| Speciality | Dentist |
| Location | 2870 Us Highway 9, Valatie, New York |
| Authorized Official Name and Position | David Starkman (PRESIDENT) |
| Authorized Official Contact | 5187587179 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Kinderhook Dental Arts Pc Po Box 788 Valatie NY 12184-0788 Ph: (518) 758-7179 | Kinderhook Dental Arts Pc 2870 Us Highway 9 Valatie NY 12184-9401 Ph: (518) 758-7179 |
| NPI Number | 1447671409 |
|---|---|
| Provider Enumeration Date | 12/18/2013 |
| Last Update Date | 12/18/2013 |
| Medicare PECOS PAC ID | 5193016004 |
|---|---|
| Medicare Enrollment ID | O20160624000126 |
News Archive
Votes are planned Thursday in the House Education and Labor and Ways and Means committees on a $1.5 trillion plan to overhaul the nation's health care system, The Associated Press reports.
Based on a systematic analysis of trials related to rheumatoid arthritis and psoriasis arthritis, a MedUni Vienna study group at the Division of Rheumatology at MedUni Vienna/Vienna General Hospital was able to show that many clinical phase II trials systematically overestimate the efficacy of therapeutics, so that the results of subsequent phase III trials can often be disappointing. Essentially this situation also applies in many other areas.
Array BioPharma Inc. has announced the presentation of preclinical data on a novel small molecule glucokinase activator (GKA), ARRY-403, a drug for the treatment of Type 2 diabetes.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the second quarter ended June 30, 2010.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447671409 | NPI | - | NPPES |
| 6531680001 | Other | NY | MEDICARE PTAN |
| 1295862258 | Other | NY | NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | 037142 (New York) | Primary |
News Archive
Votes are planned Thursday in the House Education and Labor and Ways and Means committees on a $1.5 trillion plan to overhaul the nation's health care system, The Associated Press reports.
Based on a systematic analysis of trials related to rheumatoid arthritis and psoriasis arthritis, a MedUni Vienna study group at the Division of Rheumatology at MedUni Vienna/Vienna General Hospital was able to show that many clinical phase II trials systematically overestimate the efficacy of therapeutics, so that the results of subsequent phase III trials can often be disappointing. Essentially this situation also applies in many other areas.
Array BioPharma Inc. has announced the presentation of preclinical data on a novel small molecule glucokinase activator (GKA), ARRY-403, a drug for the treatment of Type 2 diabetes.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the second quarter ended June 30, 2010.
› Verified 1 days ago
Columbia Dental Assoc. Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 18 Wilderness Ln, Valatie, NY 12184 Phone: 518-758-6359 Fax: 518-758-9359 |